HPV testing market driven by the rising incidence of cervical cancer

Press Release   •   Dec 13, 2013 10:48 GMT

The HPV testing market has been forecast to reach a value of $360 million by 2018, driven by the rising incidence of cervical cancer and the growing emphasis on early detection as a means to prevent cancer.

HPV testing is expected to gain acceptance in screening initiatives for women particularly in developed countries, due to the high level of false-negative cytology tests, and lack of proper follow up after positive test results in the current screening methods.

Also, while the incidence rate of squamous cell carcinoma has been on the decline, cervical adenocarcinoma incidence has remained largely unchanged.

Cervical cancer is one of the most prevalent forms of cancer affecting women all over the world. In most cases, the disease is attributed to genital HPV (human papilloma virus) infection. Of all the types of HPV, around 13 are considered as high-risk viruses that could progress into cancer among those infected.

As cervical cancer is a disease with long latent period, early detection and treatment of precancerous lesions is known to be highly effective in women who regularly participate in screening programs.

While cytology based testing has been the most widely used screening technique, HPV testing is steadily gaining prominence.

According to a recent market report, 'HPV Testing: A Global Strategic Business Report,' the United States represents the largest market worldwide. HPV DNA testing in the country has achieved more than 75% penetration in the ASCUS (abnormal squamous cells of undetermined significance) population, although there is still enormous potential in the co-testing market as the penetration is around 45-50%.

Growth in the domestic market will therefore be influenced by lengthening testing intervals and the fact that only 50% of the market is presently penetrated. Changes to cervical screening guidelines are also expected to influence adoption of HPV testing.

In 2012, ASCCP, ACS and ACOG endorsed co-testing while the USPSTF upgraded co-testing to Grade A, a move indicative of potential expansion in HPV testing volumes in the country.

Developing countries are also forecast to witness strong growth led by the fact that over 80% of new cases are reported annually in developing markets with high mortality rates.

The majority of the deaths due to cervical cancer in these regions are attributed to low awareness levels, poor diagnostic infrastructure and little or no access to preventive tests.

For more information on the HPV testing market, see the latest research: HPV Testing Market

Follow us on Twitter @CandMResearch issues news updates and report summaries covering all major industries and sectors. The service provides additional client monitoring and timely alerts to breaking industry and sector news leading the day's business headlines. News articles, written by our staff, contain additional analyst insight, providing value added insight for our readers. News updates and real-time alerts on newly-released market reports are also available from our Facebook page, Twitter feed @CandMResearch and RSS links. We also welcome inquiries from business journalists and the news media.